Core Message - The speech emphasizes the importance of rewiring one's mind to overcome negativity and achieve success [3][4][5] - It introduces the "WIRED" formula: Withstanding negativity, Interpreting emotions, Expanding experiences, and Designing action [4][9][11][12][19] - The speech highlights that evolution and rewiring of the mind are crucial for personal growth [3][8] Overcoming Challenges - The speech addresses common feelings of inadequacy and rejection, advocating for training the mind to break these barriers [7][8] - It stresses the need to withstand negative emotions and baggage that hinder progress [9][10] - The speaker shares a personal story of overcoming fear to illustrate the power of changing one's neural patterns [5][6][13] Action and Purpose - The speech underscores the importance of taking action and curtailing distractions to achieve goals [19][20][21] - It emphasizes the significance of having a purpose in life, stating that a life without aim is meaningless [13] - The speaker encourages appreciating what one has and stopping the complaining attitude to trigger success [15] Leadership and Success - The speech suggests that true leadership is defined by impact and influence, not just titles or knowledge [16] - It asserts that the ability to believe in oneself is the key difference between success and lack thereof [18] - The speaker uses the analogy of a bumblebee defying aerodynamics to illustrate the power of breaking self-imposed limitations [21][22][23]

Core Insights - AbbVie has announced a deal to acquire Gilgamesh Pharmaceuticals' lead pipeline candidate, bretisilocin, which is being developed for treating major depressive disorder (MDD) [1][8] Group 1: Deal Details - AbbVie will pay up to $1.2 billion for the acquisition, which includes an upfront payment and development milestones [6][8] - Gilgamesh will spin off its other drug programs into a new company, Gilgamesh Pharma, while AbbVie retains full control of bretisilocin [6][7] Group 2: Clinical Data - Bretisilocin is currently in a phase II study for moderate-to-severe MDD, showing rapid and durable antidepressant effects [2][8] - In the phase II study, bretisilocin led to a statistically significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score, with patients improving by an average of 21.6 points compared to 12.1 points for the comparator at Day 14 [2] Group 3: Market Context - AbbVie has been actively acquiring companies to strengthen its early-stage neuroscience pipeline, with recent deals including the acquisition of Aliada and Cerevel Therapeutics [9][10] - AbbVie's neuroscience portfolio has seen significant growth, with sales increasing by 20.3% to around $5 billion in the first half of 2025, driven by products like Botox Therapeutic and Vraylar [11]

AI Development & Neuroscience - The AI field is rapidly advancing, driven by unsupervised predictive learning and scaling, mirroring learning processes in the human brain's sensory cortices [5][10][14][16] - Neuroscience provides insights into AI development, particularly in areas like reinforcement learning, long-term memory (hippocampus), and continual learning [4][5][22][23][25] - AI development aims to create systems capable of learning from interaction, possessing long-term memory, and continually adapting, similar to human learning [27] Core AI Challenges - Reinforcement learning is crucial for AI to learn novel strategies by interacting with the world, building upon representations developed through unsupervised learning [17][18][19] - Long-term memory is a significant challenge, requiring AI to develop an artificial analog of the hippocampus for memory formation, consolidation, and reasoning [20][22][23] - Continual learning is essential for AI to adapt and integrate new information online, addressing the limitations of current systems with frozen knowledge [23][24][25] Ethical & Societal Implications - The development of increasingly intelligent AI systems raises concerns about potential competition with humans and the relinquishing of control to AI [28][29] - It is crucial to develop AI systems that are not only intelligent but also moral, compassionate, and selfless, ensuring that the benefits of AI are shared broadly [30][31]

Good morning one and all. I'm here to talk about my needs makeover. Let me begin with my own story.13 years of my career teaching anatomy in a medical college. No growth, no promotion, no appreciation. I felt completely stuck.In some weak moments, I started feeling myself as a failure. This is not the first time I associated with the term failure. It's all started with one deep negative seed that got rooted in my mind.When I was studying postgraduation, my mother took me to an astrologer. She was worried ab ...

RT Noland Arbaugh (@ModdedQuad)🧠 Actual Neuralink 18-Month Update 🦾Let’s just say the past 18 months haven’t exactly been boring.One moment I was booting up Eve. Next thing I know, we’re a year and a half deep, and she’s got opinions.July 28th marked 18 months since Eve and I were joined in holy matribrainy… brainimony…? A Neural Union. That’s one and a half years of telepathic typing, literal “mind over matter” moments, and countless, astonishing “Wait—did I just do that with only my thoughts?”I used to jo ...

Summary of AbbVie Conference Call Company Overview - **Company**: AbbVie - **Key Executives Present**: Rob Michael (CEO), Jeff Stewart (Chief Commercial Officer), Rupal Thakkar (Chief Scientific Officer), Scott Rents (CFO) [1] Financial Performance - **Sales Growth**: AbbVie reported a 22% sales growth from its ex-Humira platform, with combined sales from SkyRizzy and Renvoke expected to exceed $25 billion this year [2] - **Revenue Guidance**: Full-year revenue guidance raised to $60.5 billion, an increase of $800 million, with adjusted EPS guidance raised by $0.21 to a range of $11.88 to $12.08 [2][14] - **Quarterly Results**: Total net revenues for the quarter were $15.4 billion, reflecting a 6.5% operational growth [13] Product Performance Immunology - **SkyRizzy**: Global sales reached $4.4 billion, up 61.8% operationally, with strong market leadership in psoriasis and IBD [3][4] - **Rinvoc**: Global sales of $2 billion, up 41.2%, with strong uptake in IBD [4][5] - **Humira**: Global sales of $1.1 billion, down 58.2% due to biosimilar competition [5] Neuroscience - **Total Revenues**: Approximately $2.7 billion, up 24% operationally [7] - **Key Products**: - Raylar: Global sales of $900 million, up 16.3% - Botox Therapeutic: Global revenues of $928 million, up 14.2% - QLIPTA: Global sales of $338 million, up 47.2% [7] Oncology - **Total Revenues**: Nearly $1.7 billion, with global sales of Imbruvica at $2.9 billion, reflecting higher persistency rates for existing patients [5][14] Aesthetics - **Total Revenues**: Nearly $1.3 billion, down 8% operationally, impacted by economic challenges [6] - **Botox Cosmetic**: Global revenues of $692 million, with growth rates down [6] Research and Development Highlights - **Pipeline Progress**: Notable approvals include Emerilis for lung cancer and RINVOC for GCA [2][8] - **Innovative Acquisitions**: Acquisition of Capstan Therapeutics for CAR T platform and Gubra for obesity treatment [3][9] - **Alopecia Areata Results**: RINVOC showed significant hair regrowth results, with 54% of patients achieving over 80% scalp coverage [8][9] Strategic Outlook - **Long-term Growth**: AbbVie is well-positioned for growth with a diversified portfolio and plans for further investments in R&D and external innovation [20][21] - **Market Dynamics**: The company is navigating competitive pressures, particularly in the IL-23 class and aesthetics market, while maintaining strong performance in its core therapeutic areas [32] Additional Insights - **Biosimilar Impact**: The transition from Humira to newer products like SkyRizzy and Rinvoc is ongoing, with some patients opting for more efficacious drugs rather than biosimilars [16][17] - **Economic Conditions**: The aesthetics market is facing challenges due to lower consumer sentiment, but AbbVie remains optimistic about long-term growth potential [6][30] Conclusion - AbbVie demonstrated strong financial performance and growth across multiple therapeutic areas, with a robust pipeline and strategic acquisitions supporting its long-term outlook. The company is actively addressing competitive dynamics and economic challenges while positioning itself for future success.

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $150 million, reflecting a 72% increase year over year and a 24% increase quarter over quarter, driven by strong performance from Ovelity and Sunosi [6][14] - Net loss for the quarter was $48 million, or $0.97 per share, compared to a net loss of $59.4 million, or $1.22 per share in the previous quarter, and $79.3 million, or $1.67 per share in Q2 2024 [17] Business Line Data and Key Metrics Changes - Ovelity generated net product sales of $119.6 million, up 84% year over year and 24% quarter over quarter [14] - Sunosi net product revenues were $30 million, up 35% year over year and 19% quarter over quarter [15] - Zimbravo, launched on June 10, generated net sales of $410,000 for the partial quarter [15] Market Data and Key Metrics Changes - Avelity led the market in total prescriptions (TRx) growth, generating approximately 192,000 prescriptions in Q2, representing 15% quarter over quarter growth and 56% year over year growth [20] - Sunosi prescriptions exceeded 50,000 for the first time, representing 9% sequential growth and approximately 13% growth versus Q2 of last year [21] Company Strategy and Development Direction - The company is focused on advancing its late-stage neuroscience pipeline, with key priorities including AXS-five for Alzheimer's disease agitation and AXS-twelve for narcolepsy [8][10] - The launch of Cymbravo represents a significant milestone, providing new treatment options for migraine patients [7] - The company aims to expand its commercial infrastructure and enhance patient access to its medicines through strategic market access initiatives [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the accelerating trajectory of the commercial portfolio and the potential for significant long-term value creation [13] - The company anticipates continued strong commercial execution to drive momentum across its product portfolio in the second half of the year [23] Other Important Information - The company ended Q2 2025 with $300 million in cash and cash equivalents, down from $315.4 million at the end of Q2 2024 [17] - The company is on track to submit the sNDA for AXS-five this quarter and expects to initiate a Phase III trial for AXS-twelve in Q4 [9][10] Q&A Session Summary Question: Payer coverage expansion for Avelity - Management indicated that the coverage expansion represents pull-through from previously announced GPO contracts and expects some acceleration in volume [28][30] Question: Market positioning of AXS-twelve against competitors - Management expressed optimism about AXS-twelve's profile in narcolepsy, highlighting its rapid-acting nature and potential to address significant unmet needs [34][36] Question: Utilization of Cimbravo through sampling - Management reported positive early utilization of sampling programs and patient savings programs, indicating strong initial access [41][43] Question: Revenue recognition for Cimbravo - Management clarified that Q2 revenue recognition was based on initial stocking orders and that they expect to see more data on new patient starts in the coming quarters [46][48] Question: Strategy for AXS-five in Alzheimer's agitation - Management plans to leverage existing sales forces and expand promotional efforts to target geriatric psychiatry and long-term care facilities [54][56] Question: Growth drivers for Avelity - Management noted that GTN remained stable, with growth driven by higher demand and a favorable change in estimates related to liabilities [58][60] Question: Coverage expectations for Sunosi - Management aims to continue expanding coverage for Sunosi, which currently stands at approximately 83% of lives covered across channels [125] Question: Pediatric ADHD study details - Management indicated that the pediatric study will be a standard parallel group design, with confidence based on the efficacy observed in adult trials [110][112]

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: Conference Call/Webcast Information: | Date: | Monday, August 11, 2025 | | --- | --- | | Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) | | Webcast: | Pre-register here | | Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers | | Conference ID: | 4102397 | A live webcast of the company prese ...

Behavioral Finance & Risk Management - Investment banking security specialists focus on reducing risk in systems, data, and protecting people from threats, but personal ambition requires embracing risk [2][3] - Nobel laureate Daniel Kahneman's work highlights loss aversion, where the pain of losing money is greater than the pleasure of gaining the same amount, deterring investment [3][4] - Experienced traders exhibit reduced activity in the amygdala (fear) and insula (discomfort), engaging the prefrontal cortex (rational thinking) to treat losses as data, not personal threats [5][6] - Overriding fear requires a clear purpose, activating the prefrontal cortex; the "10-10-10 rule" (how will I feel in 10 minutes, 10 months, 10 years?) helps put fear in perspective [9][10] - A strong "why" releases dopamine, rewarding effort, not just outcomes, crucial for mitigating risk in cybersecurity and life [10] Overcoming Fear & Embracing Opportunity - The "why not me" approach shifts perspective, confronting the risk of not growing, rather than succumbing to imposter syndrome [12][13] - Embracing discomfort and learning from "no" leads to adaptation and growth, enabling the development of comprehensive risk management frameworks [14] - The brain is wired to avoid risk, but not regret; great achievements require outthinking the amygdala [15] - When facing "no," individuals should thank their brain for protecting them, then question "But what if I'm wrong?" [15]

Core Insights - Alkermes plc reported strong financial performance in Q2 2025, with significant growth in proprietary product sales and robust profitability [2][6][3] - The company announced positive topline results from the Vibrance-1 study of alixorexton for narcolepsy type 1, marking a key milestone in its development program [2][6] Financial Performance - Total revenues for Q2 2025 were $390.7 million, a decrease from $399.1 million in Q2 2024 [3] - Proprietary net sales increased to $307.2 million in Q2 2025, up from $269.3 million in Q2 2024, representing a growth of 14% [3][7] - Key product sales included VIVITROL® at $121.7 million (up 9% YoY), ARISTADA® at $101.3 million (up 18% YoY), and LYBALVI® at $84.3 million (up 18% YoY) [3][7] Profitability Metrics - GAAP net income for Q2 2025 was $87.1 million, compared to $91.4 million in Q2 2024 [4] - Adjusted EBITDA for Q2 2025 was $126.5 million, down from $135.3 million in Q2 2024 [4][26] - The company maintained a GAAP earnings per share of $0.52 for Q2 2025, slightly down from $0.53 in Q2 2024 [24] Research and Development - R&D expenses for continuing operations were $77.4 million in Q2 2025, an increase from $59.6 million in Q2 2024, reflecting the company's commitment to advancing its pipeline [9] - The company is preparing to initiate a global phase 3 program for alixorexton and will present detailed results from the Vibrance-1 study at the World Sleep Congress [2][6] Balance Sheet Highlights - As of June 30, 2025, Alkermes had cash, cash equivalents, and total investments of $1.05 billion, an increase from $916.2 million at the end of Q1 2025 [10][27] - Total assets reached $2.25 billion, up from $2.06 billion at the end of 2024 [27] Future Outlook - Alkermes reiterated its financial expectations for 2025, indicating confidence in its ongoing operations and product pipeline [11]